The Chinese pharma industry is one of the most significant, emerging markets and is experiencing phenomenal growth. CPHI and PMEC China organises the number 1 pharma event in the region, and we expect 55,000+ attendees at our next in-person edition.

The government is taking actions to grow the country into an R&D hub to build on its success as a manufacturing hub; China already produces 40% of the world’s APIs. Meanwhile, China’s healthcare expenditure is 7.1% relative to its GDP. All of this makes CPHI & PMEC China 2024 – happening 19-21 June – a key meeting point.